Sun Pharma launches LEQSELVI for alopecia areata after settling patent dispute with Incyte, gaining U.S. market license rights.

• Incyte accused Sun of infringing deuruxolitinib patents; both parties agreed to dismiss pending U.S. litigation.
• Sun granted a limited license for non-cancer uses of oral duruxolitinib, covering alopecia areata treatment.
• Sun is to pay upfront fees and ongoing royalties to Incyte until the eligible patents expire.